CoChat

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

Open access
Razis, Evangelia, Briasoulis, Evangelos, Vrettou, Eleni, Skarlos, Dimosthenis V, Papamichael, Dimitrios, Kostopoulos, Ioannis, Samantas, Epaminontas, Xanthakis, Ioannis, Bobos, Mattheos, Galanidi, Eleni, Bai, Maria, Gikonti, Ioanna, Koukouma, Alona, Kafiri, Georgia, Papakostas, Pavlos, Kalogeras, Konstantine T, Kosmidis, Paris, Fountzilas, George · 2008 · BMC Cancer
Cited by 90

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) is over-expressed in 70-75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGFR over-expression by immunohistochemistry (IHC). The aim of this study was to explore EGFR and the downstream effector phosphatase and tensin homologue deleted on chromosome 10 (PTEN) as potential predictors of response to cetuximab. METHODS: CRC patients treated with cetuximab by the Hellenic Cooperative Oncology group, whose formalin-fixed paraffin-embedded tumor tissue was available, were included. Tissue was tested for EGFR and PTEN by IHC and fluorescence in situ hybridization (FISH). RESULTS: Eighty-eight patients were identified and 72 were included based on the availability of tissue blocks with adequate material for analysis on them. All patients, except one, received cetuximab in combination with chemotherapy. Median follow-up was 53 months from diagnosis and 17 months from cetuximab initiation. At the time of the analysis 53% of the patients had died. Best response was complete response in one and partial response in 23 patients. In 16 patients disease stabilized. Lack of PTEN gene amplification was associated with more responses to cetuximab and longer time to progression (p = 0.042). CONCLUSION: PTEN could be one of the molecular determinants of cetuximab response. Due to the heterogeneity of the population and the retrospective nature of the study, our results are hypothesis generating and should be approached with caution. Further prospective studies are needed to validate this finding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-8-234

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 90

Metadata

Authors
Razis, E., Briasoulis, E., Vrettou, E., Skarlos, D. V., Papamichael, D., Kostopoulos, I., Samantas, E., Xanthakis, I., Bobos, M., Galanidi, E., Bai, M., Gikonti, I., Koukouma, A., Kafiri, G., Papakostas, P., Kalogeras, K. T., Kosmidis, P., & Fountzilas, G.
Venue
BMC Cancer
Published
2008-08-13
Volume
8
Issue
1
Pages
234-234
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2148156299
Cited by
90
References
8
FWCI
6.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study. https://app.cochat.ai/papers/10.1186/1471-2407-8-234
The paper
Razis, E., Briasoulis, E., Vrettou, E., Skarlos, D. V., Papamichael, D., Kostopoulos, I., Samantas, E., Xanthakis, I., Bobos, M., Galanidi, E., Bai, M., Gikonti, I., Koukouma, A., Kafiri, G., Papakostas, P., Kalogeras, K. T., Kosmidis, P., & Fountzilas, G. (2008). Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study. BMC Cancer. https://doi.org/10.1186/1471-2407-8-234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.